Should I Get a Second Opinion for Invasive Ductal Cancer?

A second opinion from a specialist breast pathologist is often a wise step, though it is not automatically required for every straightforward diagnosis. Your biopsy provides crucial information about the cancer’s type, grade, and biomarkers (proteins like estrogen and HER2 that drive cancer growth). This pathology information is combined with your imaging scans and clinical staging to plan your treatment. Having an expert confirm the details can be helpful, especially if your results show borderline biomarkers, unusual tumor features, or if your pathology report does not match what your doctor saw on your imaging scans ^[1][2].

When a Second Opinion is Most Valuable

While any patient can request a second opinion, it is highly recommended in several specific situations:

• Borderline or “Equivocal” HER2 Results: HER2 is a protein that can drive some breast cancers. An immunohistochemistry (IHC) score of 2+ is considered “equivocal” (borderline) and generally requires a second reflex test called in-situ hybridization (ISH) to determine the final status ^[3][4]. A specialist review ensures both tests are interpreted correctly to determine if you need HER2-targeted therapies.
• ER-Low Results: Estrogen receptor (ER) and Progesterone receptor (PR) status guide hormone therapy. Tumors that show ER staining in only 1% to 10% of cells are classified as “ER Low Positive.” While endocrine (hormone) therapy is still generally considered for these tumors, the benefit is less certain, and these cancers sometimes behave more like ER-negative cancers. Expert review of the staining intensity and percentage can clarify this important nuance ^[1].
• Discordance with Imaging: If your mammogram or MRI showed features suggesting extensive or higher-grade disease, but the biopsy shows only low-grade or non-invasive cells, it might be a sampling error (the biopsy needle missed the main tumor). A multidisciplinary review can help determine if the slides should be re-examined or if a repeat image-guided biopsy is needed ^[2].
• Unusual Tumor Features: Sometimes invasive ductal carcinoma (also formally called invasive carcinoma of no special type) has rare microscopic patterns—like medullary or spindle-cell features—or is hard to distinguish from invasive lobular carcinoma. A specialist can help clarify these complex diagnoses ^[5][6].
• Multiple Tumors (Multifocal Disease): If you have multiple tumor spots in the breast, their biology can sometimes differ. Your care team can determine if a specialist needs to test additional spots that look different under the microscope ^[7].

How the Review Process Works

Getting a second pathology opinion usually does not require another biopsy, unless the original tissue sample was too small or didn’t match the imaging. Instead, the tissue already removed from your body is sent to a different lab or specialist.

1. Reviewing the Slides: The consulting pathologist will evaluate the prepared glass slides from your original biopsy to assess the tumor’s morphology (its microscopic appearance), which is how the tumor’s grade is determined ^[8][9].
2. Requesting the Tissue Block: If the original slides are damaged or the specialist feels a test needs to be re-run, they will request the original tissue block (the biopsy sample preserved in wax) ^[10].
3. Additional Testing: The specialist may perform additional chemical stains (IHC or ISH) to double-check the cancer’s ER, PR, and HER2 receptor status ^[11].

How Often Do Results Actually Change?

In specific studies looking at outside pathology consultations (which often include difficult, rare, or complex cases), reviewers found some form of discrepancy in 20% to 35% of cases ^[2][9].

• Tumor Grade: The most common change during a second review is a minor adjustment to the tumor grade (how abnormal the cells look and how fast they are dividing). Pathologists sometimes disagree on whether a tumor is grade 1, 2, or 3 ^[9][12].
• Treatment Changes: While minor adjustments are common in these consultation studies, major changes that completely alter a patient’s medical treatment plan only occur in about 1% to 3% of reviewed cases ^[2][9].

Timing and Logistics

If you are scheduled to have neoadjuvant therapy (chemotherapy or targeted drugs given before surgery), the pretreatment biopsy is often your best opportunity to accurately test the untreated cancer cells for baseline biomarkers ^[13]. Once treatment begins, the drugs will alter or destroy the tumor.

Most pathology reviews take about a week to complete, but logistics like insurance and tissue release can add time. You can usually arrange a review by asking your oncologist or the original pathology department to forward your slides to a specialized breast cancer center. Do not delay your treatment on your own. You, your oncologist, and your surgeon should discuss whether waiting for the second opinion is necessary or if the review can happen in parallel with your treatment preparations ^[13].